Appili Therapeutics (Appili Therapeutics) LT-Debt-to-Total-Asset : 3.86 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Appili Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 3.86.

Appili Therapeutics's long-term debt to total assets ratio increased from Dec. 2022 (2.06) to Dec. 2023 (3.86). It may suggest that Appili Therapeutics is progressively becoming more dependent on debt to grow their business.

Appili Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Appili Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics LT-Debt-to-Total-Asset Chart

Appili Therapeutics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.16

0.09

0.05

0.59

2.41

Appili Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															2.06	2.41	3.44	3.91	3.86

Appili Therapeutics LT-Debt-to-Total-Asset Calculation

Appili Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	5.519	/	2.289
	=	2.41

Appili Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	5.659	/	1.467
	=	3.86

Appili Therapeutics (OTCPK:APLIF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Appili Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Appili Therapeutics (Appili Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

APLI:Canada

Address

1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8

Website

https://www.appilitherapeutics.com

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.